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ABSTRACT Development of effective drugs against the
rhinovirus (HRV) responsible for the common cold remains a
challenge because there are over 100 serotypes. This process
could be significantly aided by an understanding of the
atomistic mechanism by which such drugs work. We suggest
that the most effective drugs against HRV-1A act by stiffening
the pentamer channel of the viral coat through which the RNA
is released, preventing the steps leading to uncoating. Using
molecular dynamics methods we tested this Pentamer Chan-
nel Stiffening Model (PCSM) by examining the changes in
strain energy associated with opening the pentamer channel
through which the RNA is released. We find that the PCSM
strain correlates well with the effectiveness of the WIN
(Sterling–Winthrop) drugs for HRV-1A. To illustrate the use
of the PCSM to predict new drugs and to prioritize experi-
mental tests, we tested three modifications of the WIN drugs
that are predicted to be nearly as effective (for HRV-1A) as the
best current drug.
The major cause of common cold in humans is the rhinovirus
(HRV), a member of the picornavirus family. HRV exhibits
over 100 serotypes (1), making it difficult to obtain a general
effective drugs. We are using atomistic force fields (FF) and
molecular dynamics (MD) to help elucidate the atomic-level
mechanism by which current drugs operate on HRV with the
hope that this will lead to models useful in developing new
drugs that operate on all serotypes.
The serotypes of HRV are classified into two groups. The
major receptor group (including HRV-14 and HRV-16) binds
to the intercellular adhesion molecule 1 receptors. The minor
receptor group (including HRV-1A) binds to low density
lipoprotein-type receptor molecules. Both HRV-14 and
HRV-1A and their complexes with several drugs have been
studied using x-ray crystallogaphy (2–7). The protein capsid of
HRV consists of an icosahedral shell with 60 copies each of
four proteins: VP1, VP2, VP3, and VP4 (see Fig. 1), totaling
about 480,000 atoms ('300 Å diameter). This protein capsid
encloses a single-strand RNA (with about 7500 nucleotides)
inside the cavity ('100 Å diameter) of the icosahedral shell.
The 5-fold sites consist of five VP1 molecules, and are referred
to as the VP1 pentamer.
The pathway for HRV to infection is through a receptor-
mediated endocytosis. After the binding of HRV to the
cellular receptors, the VP4 clustered on the inner surface
under the pentamer channel of the VP1 pentamer comes out
through the pentamer channel. Subsequently, uncoating of
the viral capsid leads to the release of the RNA in the
cytoplasm. Although no precise sequence of events leading
to virus uncoating, after penetration has yet been proposed,
circumstantial evidence from experimental studies on po-
liovirus (same picornavirus family) justify the speculation
that RNA is released through the center of the VP1 pen-
tamer in the virus (1).
The x-ray structures for both HRV-1A and HRV-14 (6)
show a canyon surrounding the pentamer site (formed from
packing of five VP1 proteins) that is responsible for HRV
receptor interaction. This receptor binding site is a highly
conserved part on the virus shell. Several classes of compounds
active against HRV have been identified (8) including isox-
azole-derived drugs developed by Sterling–Winthrop (denoted
WIN) and by the Janssen Research Foundation (denoted R)
for HRV-14 and HRV-1A. For both HRV-14 and HRV-1A,
theWIN drugs bind to the hydrophobic pocket on VP1 (known
as the WIN pocket). Binding of the WIN drugs to HRV-14
disrupts the conformation of the residues lining the canyon
floor (the WIN pocket is below the canyon floor) by about 4
Å (9). This prevents binding to the intercellular adhesion
molecule 1 cellular receptors and thereby inhibits virus mul-
tiplication. Guha-Biswas et al. (10) analyzed the drug binding
mechanism for HRV-14 and its WIN drugs using a confor-
mational search procedure. They found that a large movement
in the residues near the WIN pocket is theoretically possible,
thus providing greater access for the entry of the drug into the
cavity in HRV-14. For HRV-1A, the WIN pocket in the native
virus is already occupied by a cofactor, possibly cellular in
origin (3, 6). In this case the WIN drugs displace the cofactor
but do not cause major conformational changes in the canyon
floor. The crystal structure of HRV-1A has a conformation
similar to that observed for drug-bound HRV-14. For drug-
bound HRV-1A there is no blocking of receptor attachment.
Because the drug is still effective, it has been speculated that
the drug action must be due to the stabilization (increased
stiffness) of the protein shell (11, 12).
We believe that interference with the uncoating process
might be a good strategy for developing a drug to act on all
serotypes of HRV, and hence we initiated FF and MD studies
of this uncoating process. Based on the speculation that the
drugs stiffen the viral capsid in HRV-1A (9) and that the RNA
is released through the pentamer channel, we propose the
Pentamer Channel Stiffness Model (PCSM): drug action on
HRV-1A constricts or stiffens the pentamer channel suffi-
ciently that the RNA andyor VP4 cannot exit, thus preventing
uncoating. In this communication we report calculations test-
ing for HRV-14 and HRV-1A and their drug complexes. We
find that drug effectiveness correlates with increased stiffness
of the pentamer channel, in support of the PCSM forHRV-1A.
The WIN drugs do not stiffen the pentamer channel for
HRV-14.We evaluated the effectiveness of modification of the
WIN drugs using the PCSM and report three new drug
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candidates that are predicted to be as effective as WIN56291,
one of the most effective drugs known for HRV1A.
The details of the calculations are described in Calculational
Details, and the results are reported in the Results section. The
Application of PCSM section contains the application of PCSM
for the design of new drugs and a discussion of the results.
CALCULATIONAL DETAILS
Force Fields. The forces between the atoms in the virus were
described using the AMBER FF (13). In AMBER, hydrogen
bonding is described in terms of Coulomb interactions (attrac-
tive) and a special two-body nonbond introduced to prevent
unphysically short approach of the hydrogen to the acceptor
atoms.
The forces involving drug molecules and cofactors were
described using the DREIDING (14) FF, known to give good
structures for such organic systems.
Structures. The starting structures for native HRV-1A and
HRV-14 and for the drug-bound systems were obtained from
x-ray crystallography (based on exact icosahedral symmetry).
The crystal structure of the asymmetric unit (by asymmetric
unit we mean the protomer) of HRV-14 contains 6649 protein
atoms (excluding hydrogens) and 272 crystallographic water
molecules. Explicit hydrogens were added to nitrogen and
oxygen atoms to allow for hydrogen bonds. The lone pair
centers required by AMBER to describe the sulfurs ofMet and
Cys were added. The resulting structure has 8521 atoms in the
asymmetric unit. The structure for several residues were
missing from the x-ray structure due to disorder. We used the
x-ray structure as available and added terminal hydrogens to
the amino terminus with appropriate AMBER charges. Using
the icosahedral symmetry elements the structures of the entire
viral coats of HRV-14 and HRV-1A were derived.
Solvation HRV-1A and HRV-14. The virus is in an aqueous
environment and hence the simulations should consider the
virus in a large box filled with water. Because of the large
number of atoms, we chose to treat the water solvent implicitly.
This is done by solvating each charged group in the protein
using appropriate counterions. We consider that this, along
with using a distance-dependent dielectric, represents the
solvation effects induced by a real bath of water. Thus Asp and
Glu are solvated by Na1 while Lys and Arg are solvated by Cl2
using special parameters (15) for the solvated counterions Na1
and Cl2. This is done for every charged group unless there is
a nearby residue of opposite charge (a salt bridge). The
dielectric constant is taken as « 5 «0R, where «0 5 1.
RNA. The RNA does not have icosahedral symmetry and
consequently it is not extracted from the crystallographic data.
Consequently we ignored the RNA in all calculations. To
determine whether this affects the structures, we carried out
Hoover constant temperature dynamics on the full 512,760-
atom protein capsid of HRV-14. We see no drift in the size of
the capsid, suggesting that the structure of the capsid is stable
in the absence of RNA.
The pentamer simulations. To determine whether the drug
affects the stiffness of the viral capsid, it is necessary to do MD
simulations on at least the full pentamer. Therefore most
calculations focused on the pentamer that included all atoms
of the VP1, VP2, VP3, and VP4 proteins for all five asymmetric
units. The resulting pentamer is solvated so that it is neutral,
leading to 42,730 atoms for HRV-14 (including crystallo-
graphic waters and counterions) and 38,840 atoms for the
HRV-1A pentamer.
Using the AMBER FF for HRV-1A and HRV-14, we
calculated the optimum geometry [converged to rms force
error of 0.1 (kcalymol)yÅ]. Table 1 shows that this leads to rms
coordinate errors of 0.34 Å and 0.40 Å (excluding the waters
and the counterions) compared with experiment for HRV-14
and HRV-1A, respectively.
The rms difference in coordinates between the starting
structure (x-ray) and the minimized structure (theory) for
various virus–drug complexes is given in Table 1, where we see
agreement to about 0.6 Å for the protein and 0.6–0.8 Å for the
drug. This is reasonable given the resolution of the experi-
ments.
The difference in the crystal structures between HRV-1A
and HRV-14 has been discussed by Kim et al. (6). The
secondary structures of the four viral proteins are similar
although the sequences are not (39% homology for VP1, 62%
for VP2, and 52% for VP3). There is a great deal of sequence
similarity in the canyon region of the various serotypes. The
structure at the neutralizing immunogenic sites (antibody
binding sites) and the GH loop of VP1 are the most variable
loops in HRV-14 and HRV-1A.
The HRV-1A cofactor. In HRV-1A the virus in its native
state has a cofactor in the WIN pocket. The cofactor in
HRV-1A was interpreted originally (3) as sucrose used in the
purification of the virus. Because sphingosine or palmitate-like
molecules have been found within the homologous pocket of
polioviruses (16, 17), the cofactor is now interpreted as a
7-carbon fatty acid (6), (C6H13)C(O)OH. To predict the struc-
ture of the protein containing this fatty acid cofactor, we
started with the crystal structure containing sucrose in HRV-
1A. We converted the sucrose to the fatty acid, placing the
FIG. 1. HRV-1A icosahedral protein coat showing 466,080 atoms,
each atom being shown as a point in the figure. VP1 is in red, VP2 in
green, VP3 in blue, and VP4 in yellow. (This figure was made using
MPSIMyPTS software developed by M. Iotov and K. T. Lim, Materials
and Process Simulation Center). The diameter is '300 Å.
Table 1. RMS variation in coordinates (Å) between the starting
x-ray structure and the minimized structure for pentamers with
and without drugs
Case Protein Drug
HRV-1A Empty 0.398
With sucrose 0.618 0.937
With WIN54954 0.628 0.824
With WIN56291 0.572 0.785
With R61837 0.649 0.684
HRV-14 Empty 0.344
With WIN52084 0.572 0.564
With r07 0.569 0.802
Crystallographic waters and counterions were excluded from the
RMS.
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carboxylate head near Asn-215 of VP1. The geometry of the
cofactor was optimized by (i) conjugate gradient minimization
of the cofactor while keeping the virus fixed until the RMS
force changes were below 0.1 (kcalymol)yÅ, and (ii) minimi-
zation of all atoms of the full cofactoryprotein complex.
The minimized structure for the fatty acid cofactor is shown
in Fig. 2. The polar head of the carboxylic acid is near (see Fig.
2) Asn-215 (4.95 Å), Thr-102 (1.98 Å from the hydrogen of the
threonyl oxygen), and Leu-103 (2.02 Å from its backbone
nitrogen) (6) and hydrogen bonded to these residues. The
hydrophobic tail of the cofactor is close to the Met-217 (4.55
Å) and Tyr-193 (4.21 Å from one of the carbons of the phenyl
ring) of VP1 as predicted by Kim et al. (6). All these residues
belong to VP1 of the viral capsid. (The coordinates of the fatty
acid are in the supplementary material; see Fig. 2 legend.)
The drug molecules. Fig. 3 shows the various WIN and
Janssen drugs examined for HRV-1A and HRV-14 (the bot-
tom two drugs in Fig. 3 are for HRV-14). There is crystallo-
graphic data on HRV-1A complex with WIN54954,
WIN56291, or R61837. In these cases the pentamer was
generated from the crystallographic data using symmetry
conditions for icosahedral symmetry. The structure of the full
drugyprotein complex was optimized, leading to drug mole-
culeyHRV structures with rms error shown in Table 1.
The crystal structures were not available for WIN52035,
WIN56278, and WIN54221. To predict the structure of
WIN52035, we replaced the two chlorine atoms of WIN54954
with hydrogens and reoptimized the pentamer–drug complex.
For WIN56278 we modified WIN54954 by adding a double
bond in the alkyl chain (Fig. 3) and reoptimized the pentamer–
drug complex. Similarly WIN54221 was built from WIN54954
by converting a single bond in the alkyl chain to a triple bond
(Fig. 3) and reoptimizing the pentamer–drug complex.
To design new drug molecules, we used the known inhibitors
as guides to build the molecules into the protein. We then
minimized the structure keeping the protein structure fixed.
This was followed by minimizing the full structure.
The Helium Balloon String Measurement of Pentamer
Stiffness.We assume that the protein decoating involves VP4
andyor RNA being released through the center of the VP1
pentamer site. To estimate how easy it is for this site to expand
to the radius required by the VP4 andyor the RNA, we
constructed a flexible string of 36 He atoms spaced by 2.0 Å.
This 70-Å string (Fig. 4 a and b) is placed along the center of
the pentamer site so that one tip is at the outer surface of the
pentameric site (see Fig. 4a) while the other is near the
VP4-VP3 complex (Fig. 4b). Starting with a vdW radius of RHe
5 0.0, the He balloon string was then slowly expanded
(allowing the He string to adjust to the shape of the pentamer
channel) while the atoms of the protein were allowed to
readjust. This was done by increasing the van der Waals radius
RHe. The increase in energy (strain) is a measure of how
difficult it is for the pentamer channel to open up as the VP4
andyor RNA is exported. As discussed below, we find signif-
icant differences in how various drugs affect the pentamer
stiffness, with a good correlation with drug effectiveness.
We used the following FF for the He. Each pair of adjacent
He atoms has a harmonic bond [Ebond 5
1
2
KR(R 2 Re)2] with
Re5 2.0 Å andKR5 2000 (kcalymol)yÅ2. The bond angle terms
is described as Eangle 5 Ku(1 1 cosu) with a minimum at u 5
1808 and ku 5 10 (kcalymol)yrad2. The He van der Waals
parameter was described as Evdw 5 Dv(r212 2 2r26), where r
5 RyRv using Dv 5 0.012 kcalymol. Rv was varied from 0 to 20
Å. The interaction of the He with the protein was described
with standard (geometric) combination rules:Rij5 =RiiRjj and
Dij5 =DiiDjj.However, allHe z z zHevanderWaals interactions
were ignored. The strain energies quoted exclude all terms
involving He.
Programs. MD calculations on the '40,000 atoms of the
pentamer and particularly the '500,000 atoms of the full
protein can become quite tedious and time-consuming, par-
ticularly because of the long-range nonbond interactions (elec-
trostatic and vdW). In addition, the use of cutoffs in these
nonbond interactions might bias the dependence of strain
energies on RHe. Consequently, we used the cell multipole
method (CMM) (19) for describing the nonbond interactions
because it does not involve distance cut-offs. To rapidly carry
out these calculations while retaining high accuracy, we used
FIG. 2. Optimized structure of the
(C6H13)C(O)OH fatty acid cofactor (red) in
HRV-1A showing the distances of the COOH
polar head of the fatty acid from the Asn-215
(purple), Leu-103 (green), and the threonyl oxygen
of the Thr-102 (blue). (The coordinates of the fatty
acid are in supplementary material that contains
the coordinates of the virus HRV-1A with the fatty
acid, and the coordinates of HRV-1A with the
drugs WIN52035, WIN54221, andWIN56278. This
material is in BIOGRAF format and is available at
http:yywww.wag.caltech.edu.)
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the MPSIM program (18). MPSIM was developed to efficiently
carry out such accurate calculations on massively parallel
computers. The calculations reported here used the Kendall
Square Research 64-node machine in the Materials and Pro-
cess Simulation Center. We used 60 processors for the full
capsid (512,760 atoms) and 25 processors for the pentamers
('40,000 atoms).
RESULTS
HRV-1A. Using the He balloon string we tested the pen-
tamer stiffness model (PCSM) for drug action on HRV-1A.
The PCSM assumes that the drug stabilizes the viral shell,
preventing uncoating. Experiments suggest that while the drug
might stiffen the viral capsid for HRV-1A, these drugs inhibit
cell binding in HRV-14 and it is not clear whether the drugs
affect uncoating in HRV-14.
Fig. 5 shows how the strain in HRV-1A pentamer increases
with the size of the He atoms. The energy required to open up
the pentamer channel for native HRV-1A is much smaller than
when drugs are present. For the native HRV-1A virus with
either sucrose or the fatty acid, the energy does not increase
rapidly until RHe 5 20 Å, whereas with drugs WIN56291 (MIC
value5 0.1mM), R61837 (MIC5 0.7 mM),WIN54954 (MIC5
2.5 mM), and WIN56278 (MIC 5 2.25 mM) the energy
increases rapidly aboveRHe5 10, 12, 14, and 14 Å, respectively.
FIG. 3. WIN and Janssen drugs for HRV-1A. The minimum
inhibitory concentration (MIC) values (in mM) are from refs. 6 and 18.
TheMIC values forMSC1, MSC2, andMSC3 shown in parenthesis are
predicted values from Fig. 6a. The bottom two drugs are for HRV-14
(MIC values are from ref. 4).
FIG. 4. The pentamer of HRV-1A with WIN56291. [These figures
were specially made by Terry Coley (Virtual Chemistry, San Diego)
using VANIMATOR software.] The He balloon string is shown in pink
and the WIN56291 drug molecules are in cyan. VP1 is in red, VP2 is
in green, VP3 is in blue, and VP4 is in yellow. (a) Top view of the
pentamer. The diameter of the region shown is '90 Å. (b) Edge-on-
view of the pentamer showing the He balloon string length (which is
70 Å long).
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[MIC values were measured by experiments (6, 20).] This
suggests that the effective drugs do indeed stiffen the pen-
tamer site of the viral coat over that of the native state. For
WIN52035 with MIC 5 4.2 mM, the energy increases rapidly
for RHe . 16 Å. This is stiffer than the native virus but is not
as high as for WIN56291. The strain energy for WIN54221 (an
inactive drug) behaves similar to the native HRV-1A with
sucrose as the cofactor, again showing the correlation between
the strain energy and the drug effectiveness.
Fig. 6a shows the variation of strain energy at RHe 5 18 Å
with 1yMIC. The fit E(RHe 5 18) 5 1255 1 1200 =(1yMIC) is
shown in dotted lines and has been used to predict the MIC
values for new drugs designed in the next section. Fig. 6b is the
RHe at which Estrain 5 1500 (kcalymol) variation with 1yMIC.
The fit Rcritical5 15.4792 1.919 log(1yMIC) has also been used
to predict theMIC values for new drugs along with Fig. 6a. The
good overall correlation supports the PCSM hypothesis that
stiffening of the VP1 pentamer site of HRV-1A correlates with
drug efficacy. Based on these results we suggest that the PCSM
be used to predict the likely drug effectiveness.
HRV-14. The WIN drugs on HRV-14 have been suggested
to have dual action of preventing cell attachment and prevent-
ing uncoating. However, it is not known if the drug prevents
uncoating for HRV-14 because the WIN drugs impedes the
cell attachment that triggers the uncoating process. In contrast,
HRV-1A attaches to the cell in spite of bound WIN drugs, yet
the virus does not uncoat, indicating that WIN impedes the
uncoating mechanism in HRV-1A. We carried out the He
balloon string studies on native HRV-14 and with the two
known WIN drugs listed in Fig. 3 (along with their MIC
values). This includes one good drug and one poor drug (high
MIC value). (The WIN pocket in HRV-14 is longer than that
of HRV-1A and hence the long alkyl chain drugs are more
effective here than on HRV-1A; the WIN drugs in HRV-14
also bind in the hydrophobic WIN pocket as in HRV-1A.) The
structure of the pentamer was minimized with the added
counterions and the crystallographic waters. The rms differ-
ence in coordinates shows fairly good accuracy of these
simulations for HRV-14 and its WIN drugs as shown in Table 1.
Fig. 7 shows the strain energy versus RHe for HRV-14 and its
WIN drugs. According to PCSM, the HRV-14 virus shows no
stiffening of the pentamer channel when the drug is present.
Here we see no special correlation of the strain induced by r07
and WIN52084 with their MIC values. That is, although
WIN52084 has a low MIC value of 0.03, the PCSM does not
lead to stiffening greater than r07 (whose MIC is 2.4). These
results suggest that inhibition of uncoating is not the major
effect of the current drugs on HRV-14.
Phelps and Post (21) used stochastic MD simulations to
study the compressibility of HRV-14 with and without the
WIN52084 drug. The compressibility was calculated using MD
for about 3000 atoms surrounding the WIN pocket. They find
a higher compressibility for the viral coat with WIN52084 than
FIG. 5. Pentamer stiffness for HRV-1A with various WIN and R
drugs. The MIC values (in mM) in parenthesis are from refs. 6 and 20.
FIG. 6. Comparison of pentamer stiffness with MIC for various
HRV-1A–drug complexes. (a) The strain energy at RHe 5 18 Å. The
values in parenthesis are the MIC values from reference 6 and 18. The
dashed curve is the fit to Estrain(18 Å) 5 1255 1 1200=(1yMIC). For
MSC1, MSC2, and MSC3 the predicted MIC values are shown on the
fitted curve. (b) The radius at which Estrain 5 1500 kcalymol. The
dashed curve is the fit to Rcrit 5 15.479 2 1.919 log(1yMIC). The
predicted MIC values for MSC1, MSC2, and MSC3 are shown on the
fitted curve.
FIG. 7. Pentamer stiffness for HRV-14 with various WIN drugs.
The MIC values (in mM) in parenthesis are from ref. 4.
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without the drug, suggesting that a more compressible coat
leads to a better drug. The increase in compressibility in
HRV-14 perhaps explains the lack of cell attachment.
APPLICATION OF PCSM
New Drugs. To illustrate how one might use the atomic
mechanism to design new drugs, we modified the best drug,
WIN56291. It is known that WIN56291 is a better drug for
HRV-1A than WIN54954 whereas the opposite is found for
HRV-14. The difference between these drugs (Fig. 3) is that
the length of the alkyl chain between the iso-oxazole ring and
the phenyl oxazole rings is shorter for WIN56291. This differ-
ence in effectiveness probably arises because HRV-1A has a
shorter (6) WIN pocket than HRV-14. Hence, a shorter drug
might be more effective for HRV-1A than for HRV-14. Based
on this we speculated that a new drug (denoted MSC1) where
the alkyl chain is completely removed from WIN56291 (with
only the ether like oxygen remaining in the alkyl chain) would
be more effective for HRV-1A. To test this idea we optimized
MSC1yHRV-1A and calculated the strain (Fig. 5). The energy
increase starts at about the same radius as WIN56291 and
Rcritical ' 14 Å for MSC1. The MIC value of MSC1 calculated
from the fit to Fig. 6a is '0.13 mM. Thus according to PCSM,
MSC1 should be comparable in effectiveness to WIN56291.
This could be due to the removal of the flexible alkyl chain in
WIN56291 by a rigid ether-like linkage (22) that makes MSC1
less volume filling.
A second new drug (MSC2) was built by removing the two
chlorines on the phenyl ring of MSC1. The drug with the
optimized viral coat of theMSC1 was further optimized for the
structure of MSC2. This was done by first keeping the pen-
tamer of the viral coat fixed, and MSC2 is relaxed during the
minimization. Later a full minimization was done with both the
viral coat and MSC2 movable. The strain energy reached the
value of 1500 Kcalymol at Rcritical 5 14.5–15 Å (Fig. 5) unlike
MSC1 which has a smaller Rcritical. The MIC value predicted
from PCSM is '0.20 mM. This again is the expected trend as
has been observed in WIN54954 and WIN52035. The phenyl
ring of the drug is surrounded by residues such as like Cys-76,
Tyr-240, and Lys-112 that have a high pKa. This cavity is
favorable for the chlorine atoms on the phenyl ring (due to
possiblep bonding interactions with the Tyr-240) ofMSC1 and
hence MSC1 shows more stiffening than MSC2 which has no
chlorines.
We thought that lengthening the chain in MSC1 by one CH2
group might improve drug effectiveness by making it more
flexible. Hence we built and optimized MSC3 (Fig. 3). The
PCSM correlation for MSC3 with RHe is also shown in Fig. 5.
The predicted value ofMIC forMSC3 is'0.16 mM, andMSC3
seems to be a better drug in stiffening the pentamer channel
than MSC2.
Summary. We carried out FF and MD calculations to test
the pentamer stiffness model (PCSM) for uncoating of HRV.
We find that the pentamer channel through which the RNA is
released during uncoating is constricted when WIN drugs are
bound to HRV-1A but not without the drug. The stiffness
correlates with drug effectiveness. For HRV-14 we find that
the effect of drugs on stiffness do not correlate with efficiency.
These results support the PCSM and provide a correlation that
could be used to aid drug design.
We designed three new molecules (MSC1, MSC2, and
MSC3) and used the PCSM to assess their likely effectiveness
on HRV-1A. We find that MSC1 leads to as good a constric-
tion of pentamer channel of HRV-1A as the best known drugs.
Of course an effective drug must have many properties not
tested by the PCSM. It must be delivered to the appropriate
site and it must displace whatever might already be in the site.
However, we believe that the PCSM could be useful for rapid
screening of new candidate drugs before subjecting them to
more expensive experimental procedures. Because all sero-
types of HRV must uncoat (even though they may bind to
different cellular receptors), use of PCSM to develop drugs
specifically directed toward pentamer stiffness might help
develop drugs effective against all serotypes.
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